Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ress in advancing programs within its late-stage development pipeline. These programs have significant potential to drive the company's growth beyond 2011.

Mozobil(TM) (plerixafor) for stem-cell transplantation

-- Genzyme plans to file mid year for U.S. and European approval for

Mozobil's use in treating patients with multiple myeloma and patients

with lymphoma. The company expects to launch the product in the United

States early next year upon approval and to rapidly expand the

product's availability around the world. The company anticipates peak

annual sales of the product in the transplant setting of $400 million.

Mozobil is an innovative product intended to enhance the mobilization

of stem cells for transplantation in patients with lymphoma and

multiple myeloma. In two pivotal clinical studies, Mozobil showed the

ability to quickly and predictably prepare cancer patients for a

transplant to treat their disease. Genzyme is also exploring

additional indications for Mozobil, including its potential use in

chemosensitization procedures.

Clolar for adult AML

-- Clolar is approved in the United States and Europe for the treatment of

acute lymphoblastic leukemia in relapsed and refractory pediatric

patients. Genzyme is developing the product for use globally as a

first-line therapy for the treatment of adult acute myeloid leukemia

(AML) and myelodysplastic syndromes, significantly larger indications

that the company estimates will drive peak annual sales of the product

to approximately $600 million. The company intends to submit a

supplemental new drug application in the United States later this year

to include an adult AML indication. This application will be based on

results from the CLASSIC II clinical trial involving older adult AML

<
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... City, CA (PRWEB) , ... August 31, 2015 , ... ... System. Minerva is the first commercially available new FDA approved system in ... treatment Success rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the ...
(Date:8/31/2015)... ... ... Proove Biosciences, Inc. is a finalist for the Outstanding Tech Company category of ... its 22nd year, this premier awards event celebrates the best in Orange County’s technology ... world. The OC Tech Alliance will announce all winners at a gala dinner on ...
(Date:8/30/2015)... , England , August 31, ... beendet die 51-jährige Wartezeit   einer Frau   für ... Frauen im Alter von 7-90   werden ... Programm soll 1200 Frauen behandeln und die ... , Astellas gab heute bekannt, ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zsgg5n/global_and_usa ) ... USA BioSimilar Market Analysis to 2021" report to ... market will be initiated in September as Sandoz launches ... global market react? Will biosimilars explode into the biologics ... US economy up to $250 billion within the next ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... law firm of Finkelstein,Thompson LLP announces that a class ... Court for the Southern District of New York on,behalf ... GPC Biotech AG,("GPC Biotech" or the "Company") (Nasdaq: ... inclusive (the "Class Period"). Finkelstein Thompson LLP,is investigating similar ...
... BioSciences Inc.,(AMEX: YMI , TSX: YM, AIM: ... differentiated products for patients worldwide,today announced that Oncoscience ... of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has advised ... commence in Europe. - A ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... shareholders today that the Annual General Meeting ... been postponed due the geographical,nature of its ... of,proxy materials. The Company is currently working ...
Cached Biology Technology:Finkelstein Thompson LLP Announces GPC Biotech AG Investigation 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Sinovac Announces Postponement of Annual General Meeting 2
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... NEW YORK, July 6, 2011 Reportlinker.com announces ... in its catalogue: Biobanking: Technologies ... REPORT HIGHLIGHTS ... * An overview of biobanks by types: Population, ...
... become as common as the stethoscope in patient,s rooms. Physicians ... access diagnostic tools and take patient notes, all with a ... a flash drive. These mobile devices are ideal for information ... to patient information. In less than two years, ...
... Accelerator announced today that it has received an investment ... the Silicon Valley. Mr Draper, who is the Founder ... is well known for making early-stage investments in dynamic ... is a technology incubator that focuses on commercialising key ...
Cached Biology News:Biobanking: Technologies and Global Markets 2Biobanking: Technologies and Global Markets 3Biobanking: Technologies and Global Markets 4Biobanking: Technologies and Global Markets 5Biobanking: Technologies and Global Markets 6Biobanking: Technologies and Global Markets 7Biobanking: Technologies and Global Markets 8Biobanking: Technologies and Global Markets 9Biobanking: Technologies and Global Markets 10Biobanking: Technologies and Global Markets 11Biobanking: Technologies and Global Markets 12Biobanking: Technologies and Global Markets 13Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 2Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 3Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 4Mobile Devices Pose New Security Risks for Patients; Five Experts Share Insights on mHealth 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6
Request Info...
... Xcell microbial system, 100 to 240 ... electroporation of bacterial and fungal cells. ... PC module for exponential decay delivery, ... (5 each of 0.1 and 0.2 ...
... Species Tissue Array (MSTA) slides were designed to ... tissues from multiple species. Tissue slices from ... slide which can then be treated as a ... in situ hybridization. This format ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
Biology Products: